Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

[1]  Barney S. Graham,et al.  Rapid COVID-19 vaccine development , 2020, Science.

[2]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[3]  T. Monath,et al.  rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment , 2019, Vaccine: X.

[4]  J. Ravetch,et al.  Attenuated Vaccines for Augmented Immunity. , 2017, Cell Host and Microbe.

[5]  Robert T. Chen,et al.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. , 2016, Vaccine.

[6]  P. Minor.  Live attenuated vaccines: Historical successes and current challenges. , 2015, Virology.

[7]  R. Andino,et al.  Rationalizing the development of live attenuated virus vaccines , 2010, Nature Biotechnology.

[8]  Robert T. Chen,et al.  Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. , 2009, Vaccine.

[9]  Robert T. Chen,et al.  The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). , 2002, Vaccine.

[10]  Robert T. Chen,et al.  The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). , 2015, Vaccine.

[11]  Robert T. Chen,et al.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. , 2015, Vaccine.